YAKUGAKU ZASSHI
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
誌上シンポジウム
次世代型“包括的がん緩和医療”への取り組み—抗がん剤による耐性獲得及びがん増悪化の分子理解
葛巻 直子成田 道子池上 大悟成田 年
著者情報
ジャーナル フリー

2016 年 136 巻 5 号 p. 699-703

詳細
抄録

 Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. However, the application of gefitinib is ultimately limited by the emergence of mutations and other molecular mechanisms conferring drug resistance. Furthermore, it has been considered that acquired resistance to gefitinib is associated with a clinically significant risk of accelerated disease progression. We previously established a new gefitinib-resistant NSCLC cell line, HCC827GR, which harbors the T790M mutation. Using HCC827GR, we found that the inhibition of adenosine A2a receptors of NSCLC regulated cancer proliferation and exacerbation, indicating that adenosine A2a receptors may be new targets for a novel strategy in NSCLC therapy. These findings suggest that multilayered crosstalk between G-protein coupled receptors (GPCRs) and EGFR may play an important role in regulating downstream signaling molecules that are implicated in the development of gefitinib-resistant NSCLC.

著者関連情報
© 2016 The Pharmaceutical Society of Japan
前の記事 次の記事
feedback
Top